Related by context. All words. (Click for frequent words.) 77 prostate carcinoma 75 malignant pleural mesothelioma 75 papillary renal cell carcinoma 74 renal tumors 74 peritoneal carcinomatosis 74 histological subtype 74 HNSCC 74 renal cell carcinomas 74 operable breast cancer 74 breast carcinoma 74 nonmetastatic 74 prostate cancer CaP 74 urothelial carcinoma 73 colorectal carcinoma 73 epithelial tumors 73 mucinous 73 ovarian carcinoma 73 cisplatin resistant 73 radiochemotherapy 73 GISTs 72 urothelial cancer 72 fallopian tube carcinoma 72 gastric adenocarcinoma 72 gastric cancers 72 LHRH receptor positive 72 renal carcinoma 72 metastatic lung cancer 72 squamous cell carcinoma SCC 71 medically inoperable 71 chemoresistant 71 carcinoid tumors 71 biliary tract cancer 71 chemoradiotherapy 71 colon carcinoma 71 metastatic renal cell carcinoma 71 prostate adenocarcinoma 71 gastric carcinoma 71 bladder carcinoma 71 unresectable tumors 71 seminoma 71 sarcomatoid 71 nasopharyngeal carcinoma 71 metastatic malignant melanoma 71 colorectal adenocarcinoma 71 neoadjuvant chemotherapy 71 metastatic gastric 71 breast carcinomas 71 liver metastasis 71 NMIBC 71 recurrent NSCLC 71 castrate resistant 71 lung adenocarcinomas 71 xenograft tumors 71 K ras mutations 71 gefitinib Iressa 70 mutated KRAS 70 paragangliomas 70 leukemia AML 70 cervical carcinoma 70 metaplasia 70 distant metastases 70 hepatoma 70 epithelial ovarian 70 basal cell carcinoma BCC 70 recurrent glioblastoma multiforme 70 allogeneic hematopoietic stem cell 70 haematopoietic 70 pulmonary metastases 70 hamartomas 70 thyroid carcinoma 70 cervical lymph nodes 70 underwent resection 70 ADPKD 70 ErbB2 positive 70 HER2 positive metastatic breast 70 node metastases 70 lung carcinomas 70 pulmonary metastasis 70 colorectal liver metastases 70 pT2 70 clinicopathological 70 pancreatic carcinoma 70 ductal adenocarcinoma 70 locoregional disease 70 metastatic malignant 70 hematopoietic cancers 70 Papillary 70 GBM tumors 69 locoregional 69 SSc 69 osteosarcomas 69 paraganglioma 69 neoplastic 69 thymoma 69 nodal metastases 69 squamous 69 lymphoproliferative disorders 69 malignant prostate 69 antiangiogenic therapy 69 metastatic RCC 69 stage IIIB 69 prostate cancer CRPC 69 nonsmall cell lung cancer 69 nodal metastasis 69 distant metastasis 69 cholangiocarcinoma 69 metastatic colorectal 69 skeletal metastases 69 HSCT 69 lymph node metastasis 69 lung metastases 69 squamous cell lung cancer 69 Gleevec resistant 69 malignant neoplasm 69 metastatic bladder 69 histologic subtype 69 tumor histology 69 stage IIIA 69 bladder cancers 69 carcinoid 69 PCa 69 KRAS wild 69 atypical hyperplasia 69 radical nephrectomy 69 resectable 69 malignant lymphoma 69 pegylated liposomal doxorubicin 69 metastatic neuroendocrine tumors 69 bronchogenic carcinoma 69 Renal Cell Carcinoma RCC 69 KRAS mutations 69 cutaneous melanoma 69 histologies 69 metastatic pancreatic 69 invasive ductal 69 lymph node metastases 69 cytoreduction 69 lobular carcinoma 69 TACE 69 serous ovarian cancer 69 neoadjuvant therapy 69 antiproliferative effects 69 hepatocellular carcinomas 69 pleural mesothelioma 69 Chronic lymphocytic leukemia 69 HER2 positive cancers 68 papillary carcinoma 68 Hepatocellular Carcinoma HCC 68 histological subtypes 68 Hurthle cell 68 adenocarcinomas 68 cranial irradiation 68 Prognostic factors 68 Doxil ® 68 papillary 68 lymphoid cells 68 leiomyomas 68 breast pancreatic 68 immunohistochemical staining 68 BRAF V#E 68 neoadjuvant treatment 68 situ LCIS 68 multiple myeloma MM 68 concurrent chemoradiation 68 mRCC 68 intestinal metaplasia 68 sorafenib Nexavar ® 68 metastatic GIST 68 pT3 68 locoregional recurrence 68 transplantation HCT 68 hematopoietic cell 68 supratentorial 68 metastatic lesions 68 heavily pretreated 68 preoperative chemotherapy 68 tumoral 68 LV dysfunction 68 neoplastic cells 68 localized renal 68 idiopathic myelofibrosis 68 mycosis fungoides 68 gastrointestinal cancers 68 mutated K ras 68 liver metastases 68 follicular lymphomas 68 p# biomarker 68 papillary thyroid carcinoma 68 lymphoid malignancies 68 epithelial ovarian cancer 68 differentiated thyroid 68 KRAS mutation 68 pancreatic islet cell 68 T1c 68 Surgical resection 68 lymph node involvement 68 lobular breast cancer 68 MALT lymphoma 68 lymphocytosis 68 leiomyosarcoma 68 myeloproliferative disorders 68 leiomyoma 68 essential thrombocythemia 68 endometrial cancers 68 basal cell nevus syndrome 68 imatinib Gleevec 68 pancreatic lung 68 advanced adenomas 68 breast cancer subtypes 68 KRAS status 68 MYCN amplification 68 pretransplant 68 prognostic variables 67 carcinoid tumor 67 recurrent glioblastoma 67 castration resistant prostate cancer 67 xenograft models 67 pancreatic cancers 67 prostate cancer PCa 67 malignant lymphomas 67 IV NSCLC 67 microsatellite instability 67 neoadjuvant 67 pCR 67 grade gliomas 67 stage IIIb IV 67 squamous histology 67 MGUS 67 histologic subtypes 67 immunocompetent 67 ependymoma 67 recurrent metastatic 67 NSCLC 67 clinically localized prostate 67 postoperative chemotherapy 67 nonmelanoma skin cancers 67 mCRC patients 67 pheochromocytoma 67 ccRCC 67 prognostic indicator 67 ductal carcinomas 67 androgen independent 67 carcinoma 67 invasive carcinoma 67 Hodgkin lymphoma HL 67 anaplastic 67 biliary cancer 67 EGFR mutation positive 67 PROSTVAC VF 67 histopathologic examination 67 resected pancreatic cancer 67 stage IIIB IV 67 Metastatic 67 Squamous 67 relapsed SCLC 67 epithelioid 67 HER2 expression 67 thoracoscopic lobectomy 67 CTAP# Capsules 67 Waldenstrom macroglobulinemia 67 T1a 67 cytoreductive surgery 67 acute myeloid 67 metastatic lymph nodes 67 diabetes mellitus DM 67 relapsed MM 67 taxane therapy 67 GIST tumors 67 premalignant 67 HER2 overexpression 67 adjuvant radiotherapy 67 colorectal metastases 67 completely resected 67 hepatocellular carcinoma HCC 67 oligodendrogliomas 67 hormone refractory 67 biochemical recurrence 67 neuroendocrine cancers 67 metastases 67 cystectomy 67 breast endometrial 67 radiotherapy RT 67 malignant ascites 67 Radical prostatectomy 67 Sezary syndrome 67 neoplasias 67 hepatocellular carcinoma 67 refractory colorectal cancer 67 orthotopic 67 bladder tumors 67 prostate carcinomas 67 ductal breast cancer 67 hepatocellular cancer 67 Cholangiocarcinoma 67 transitional cell carcinoma 67 castration resistant 66 kidney urologic 66 underwent surgical resection 66 chemoembolization 66 pleomorphic 66 KRAS mutations occur 66 poorer prognosis 66 esophageal carcinoma 66 castrate resistant prostate cancer 66 NSCLC tumors 66 intravesical therapy 66 SCCHN 66 Glioblastoma Multiforme 66 hyperplastic 66 pituitary adenomas 66 extramedullary 66 clinico pathological 66 metastatic prostate cancer 66 refractory ovarian cancer 66 KRAS mutant 66 gastrointestinal stromal tumor 66 thrombocytopenic 66 nondiabetic patients 66 EGFr 66 Carcinoma 66 carcinoma HCC 66 metastatic lesion 66 situ CIS 66 thyroid nodules 66 fallopian tube cancers 66 metastatic 66 oral squamous cell 66 neoplasm 66 Leydig cell 66 CYT# potent vascular disrupting 66 primary hyperparathyroidism 66 Leukemias 66 T#I [002] 66 allogeneic transplant 66 metastatic prostate 66 neoplastic lesions 66 metastatic renal cell 66 histologically 66 malignant fibrous histiocytoma 66 superficial bladder cancer 66 transplantation HSCT 66 precursor lesions 66 colorectal cancer CRC 66 demonstrated antitumor activity 66 adjuvant radiation 66 de novo AML 66 tumor recurrence 66 malignant pancreatic 66 contralateral breast 66 gastrointestinal stromal tumors GISTs 66 imatinib therapy 66 uveal melanoma 66 lobular carcinomas 66 Glioblastoma Multiforme GBM 66 neurofibromas 66 Anaplastic 66 lung adenocarcinoma 66 metastatic tumors 66 glioblastoma tumors 66 lymphadenectomy 66 endometrial hyperplasia 66 radical prostatectomy RP 66 renal cell carcinoma 66 chemo resistant 66 BCG refractory 66 HBeAg negative 66 immunohistochemical 66 malignant growths 66 medullary thyroid cancer 66 peritoneal cancer 66 ovarian pancreatic 66 Immunohistochemical analysis 66 colorectal tumor 66 androgen deprivation 66 KRAS oncogene 66 neuroendocrine tumors 66 sorafenib Nexavar 66 lung metastasis 66 percutaneous biopsy 66 carcinomas 66 allogeneic stem cell 66 pro angiogenic 66 Adjuvant therapy 66 TIMP 1 66 micrometastases 66 hepatorenal syndrome 66 invasive lobular carcinoma 66 CR nPR 66 neuroendocrine carcinoma 66 syngeneic 66 papillary RCC 66 gastrointestinal stromal tumor GIST 66 biochemical relapse 66 premalignant lesions 66 bleomycin 66 haematopoietic stem cell 66 adrenocortical cancer 66 clinicopathologic 66 N. Engl 66 leukemia CLL 66 standard chemotherapy regimens 66 B7 H3 66 colorectal tumors 66 ALI ARDS 66 colorectal gastric 66 esophageal squamous cell carcinoma 66 gemcitabine carboplatin 66 cell lymphoma CTCL 66 EGFR mutations 66 urothelial bladder cancer 66 smoldering myeloma 66 seminomas 66 PKCi 66 elacytarabine 66 imatinib resistant 66 radiosensitivity 66 malignant ovarian 66 metastatic basal cell 66 intestinal polyps 66 visceral metastases 66 Medullary thyroid cancer 66 unresectable stage 66 hypermethylated 66 thymic carcinoma 66 lymphocytic leukemia 66 adenomatous 66 recurrent GBM 66 cytologically confirmed 66 acute leukemias 65 tumor xenograft models 65 tumors GIST 65 neoplasia 65 soft tissue sarcomas 65 invasive lobular 65 xenografts 65 neoplasms 65 mTOR inhibitors 65 bevacizumab Avastin ® 65 essential thrombocythemia ET 65 small lymphocytic lymphoma 65 ALND 65 BRAF V#E mutation 65 pancreatic endocrine 65 colorectal adenoma 65 lymphoid tumors 65 thalidomide Thalomid 65 TOP2A 65 prostate pancreatic 65 nephron sparing surgery 65 PNET 65 CLL cells 65 angiosarcoma 65 glioblastoma multiforme GBM 65 Endometrial 65 dasatinib Sprycel 65 T2DM 65 haematologic malignancies 65 gastric cardia 65 FOLFOX4 65 gemcitabine Gemzar 65 metachronous 65 Immunohistochemical staining 65 carcinoids 65 EUS FNA 65 plasmacytoid 65 estrogen receptor ER 65 BRCA deficient 65 PSADT 65 acute lymphoblastic 65 HIPEC 65 histologically confirmed 65 normal karyotype 65 thyroid carcinomas 65 mesotheliomas 65 astrocytoma 65 gadolinium enhanced 65 tumor metastases 65 cediranib 65 invasive ductal carcinoma 65 RRM1 65 Multiple Myeloma MM 65 carboplatin paclitaxel 65 HER2 negative 65 WT1 65 platinum refractory 65 leukaemias 65 Adjuvant chemotherapy 65 metastatic cancer 65 B Cell Lymphoma 65 neuroblastomas 65 heavily pretreated patients 65 debulking surgery 65 lung tumors 65 chemoradiation 65 axillary dissection 65 CYPHER Stent 65 Sjögren syndrome 65 prostate cancer HRPC 65 Atypical Hemolytic Uremic Syndrome 65 BRCA1 mutation carriers 65 nasopharyngeal cancer 65 urothelial 65 cardiac dysfunction 65 imatinib resistance 65 PROLARIS 65 ovarian breast 65 surgically resectable 65 untreated metastatic melanoma 65 spontaneous regression 65 osteoid 65 Glioma 65 metabolomic profiles 65 trans retinoic acid 65 endocrine therapies 65 SHPT 65 antitumor effect 65 CMV disease 65 anti angiogenic agents 65 cisplatin gemcitabine 65 adenocarcinoma 65 chronic periodontitis 65 pancreatic ovarian 65 sentinel lymph node biopsy 65 radiosensitive 65 gastrointestinal stromal tumors GIST 65 unresectable 65 Mitomycin C 65 anti angiogenic therapy 65 preoperative staging 65 allogeneic HSCT 65 undergoing hematopoietic stem 65 SLNB 65 PCNSL 65 hepatic metastases 65 Soft Tissue Sarcoma 65 preoperative PSA 65 CDH1 65 stage IIIb 65 malignancies 65 decitabine 65 pediatric acute lymphoblastic 65 FLT3 65 esophagogastric junction 65 intraperitoneal chemotherapy 65 HER2 positive breast 65 multivariate analyzes 65 advanced epithelial ovarian 65 ovarian lung 65 nephrectomy 65 Radiofrequency ablation 65 BRCA mutation carriers 65 metastatic uveal melanoma 65 carcinoembryonic antigen 65 gastrointestinal stromal tumors 65 hA# 65 myeloid metaplasia 65 liver resection 65 Proxinium TM 65 tyrosine kinase inhibitors 65 malignant cancerous 65 neuroblastoma tumors 65 nutlin 3a 65 ipsilateral breast 65 familial pancreatic cancer 65 metastatic ovarian cancer 65 pancreatic colon 65 cystic lesions 65 temozolomide TMZ 65 pancreatic ductal 65 irinotecan chemotherapy 65 myeloproliferative neoplasms 65 Metastatic breast cancer 65 cell carcinoma 65 Sipuleucel T 65 axillary lymph nodes 65 elevated LDH 65 transthyretin amyloidosis 65 EGFR receptor 65 histologically proven 65 Chronic Lymphocytic Leukemia CLL 65 hematological relapse 65 TKI therapy 65 Neoadjuvant 64 tumor subtypes 64 Synovial sarcoma 64 pancreatic prostate 64 esophagogastric 64 depsipeptide 64 pain palliation 64 primitive neuroectodermal tumor 64 endometrial carcinoma 64 APOL1 64 myeloproliferative disorder 64 benign neoplasms 64 chemoradiation therapy 64 DNA methylation patterns 64 parathyroid carcinoma 64 Myelodysplastic Syndrome MDS 64 bladder ovarian 64 #F FDG PET 64 vinca alkaloid 64 epithelial cancers 64 GSTP1 64 refractory metastatic 64 adrenalectomy 64 carotid stenosis 64 tumorigenicity 64 oblimersen 64 baseline LDH 64 non squamous NSCLC 64 leukemia ALL 64 gastric cancer 64 Flu Cy 64 cisplatin chemotherapy 64 ANCA associated 64 myeloablative 64 nonalcoholic steatohepatitis NASH 64 HIV HCV coinfected 64 synovial sarcoma 64 EGFR inhibitors 64 autologous transplants 64 HGPIN 64 metastatic carcinoma 64 chemosensitivity 64 Anthracycline 64 malignant brain 64 cell carcinomas 64 EpCAM 64 adjuvant therapies 64 follicular thyroid cancer 64 relapsed AML 64 mononuclear cells 64 transarterial 64 non resectable metastatic 64 miRs 64 recurrent malignant glioma 64 LRP5 64 hepato 64 hormone receptor negative 64 Fas ligand 64 busulfan 64 chromosomal mutations 64 ER CHOP 64 ductal cancer 64 liposarcoma 64 benign nodules 64 allogeneic transplants 64 histologic findings 64 EGFR HER2 64 Rectal cancer 64 trabectedin 64 antiangiogenic agent 64 BRCA1 mutations 64 familial ALS 64 Her2/neu 64 p# mutations 64 intratumoral injection 64 non squamous 64 hormone receptor status 64 haematologic 64 CP CPPS 64 DLBCL 64 dyskeratosis congenita 64 surgical debulking 64 paricalcitol 64 mycophenolate mofetil 64 intraductal 64 galiximab 64 hepatectomy 64 thrombocytosis 64 myeloproliferative diseases 64 perioperative complications 64 progesterone receptor PR 64 varicoceles 64 CALGB 64 thymectomy 64 liver transplant recipients 64 CIN2 + 64 alveolar rhabdomyosarcoma 64 lymphomas leukemias 64 sunitinib Sutent 64 thyroglobulin 64 lymphocytic 64 polycythemia vera PV 64 geographic atrophy 64 CIN3 64 erlotinib Tarceva ® 64 RTOG 64 HepG2 cells 64 myelomas 64 neovascular 64 Circulating tumor cells 64 pelvic lymphadenectomy 64 benign moles 64 CC genotype 64 EGFR mutation 64 extracranial 64 HER2 receptor 64 chlorambucil 64 endoscopic ultrasonography 64 Myelodysplastic Syndrome 64 Wilms tumors 64 osteoblastic 64 external beam radiotherapy 64 advanced adenoma 64 chondrosarcoma 64 meningiomas 64 tumor xenografts 64 fibroma 64 teratoma 64 pancreatic NET 64 ERBB2 64 myeloid leukemia 64 breast cancer metastasis 64 prognostic significance 64 Pemetrexed 64 intracranial tumors 64 sCD# 64 chronic lymphocytic leukemia CLL 64 acute aortic dissection 64 clonogenic 64 sCJD 64 MSH2 64 adjuvant tamoxifen 64 JMML 64 recurrent ovarian cancer 64 basal cell skin 64 ALA PDT 64 pertuzumab 64 Acute myeloid leukemia 64 EGFR mutant 64 graft dysfunction 64 lesional 64 invasive bladder 64 hamartoma 64 relapsed ALL 64 hypereosinophilic syndrome 64 EGFR tyrosine kinase inhibitors 64 localized prostate 64 AGTR1 64 hematological diseases 64 antiretroviral naïve 64 adenomatous polyps 64 Aplidin 64 azacytidine 64 haematological cancers 64 astrocytomas 64 5 fluorouracil leucovorin 64 submandibular gland 64 Estrogen Receptor 64 TRAIL R1 64 follicular lymphoma FL 64 familial amyloidotic polyneuropathy FAP 64 prostate cancer mCRPC 64 HRPC 64 systemic lupus erythematosus 64 prospective multicenter study 64 metastatic melanomas 64 chemotherapeutic regimens 64 Relapsed Refractory 64 Kaplan Meier analysis 64 adjuvant systemic 64 Mesenchymal 64 bronchoalveolar lavage BAL 64 HER2 neu 64 Lymph node 64 laparoscopic radical nephrectomy 64 liposomal doxorubicin 64 Lung transplantation 64 LVNC 64 Allogeneic 64 complete cytogenetic response 64 relapsed multiple myeloma 64 PsA 64 myelofibrosis polycythemia vera 64 Belldegrun 64 LHRH agonists 64 monoclonal gammopathy 64 lenalidomide Revlimid R 64 advanced unresectable 64 MGd 64 fulvestrant 64 colorectum 64 monocytic 64 Candida infection 64 IPAH 64 cancer mCRC 64 underwent liver transplantation 64 allogeneic bone marrow 64 BRAF mutation 63 ADVEXIN therapy 63 NOD SCID mice 63 tumor subtype 63 lymphangiogenesis 63 histologic diagnosis 63 atherosclerotic lesions 63 Malignant Melanoma 63 trastuzumab Herceptin ® 63 portal vein thrombosis 63 Cutaneous T 63 resections 63 oncologic outcomes 63 gemcitabine chemotherapy 63 perioperative morbidity 63 clinicopathological features 63 HER2 positive tumors 63 miR #a [001] 63 ERK1 2 63 transgene expression 63 hepatic fibrosis 63 Diffuse Large B 63 proliferative disorders 63 glioblastoma 63 indolent lymphomas 63 bone metastasis 63 CLL SLL 63 esophagectomy 63 stem cell engraftment 63 pan HDAC inhibitor 63 nonischemic 63 huN# DM1 63 pilocytic astrocytomas 63 etoposide 63 refractory NSCLC 63 Fibroblast 63 immunohistochemical analysis 63 progesterone receptor negative 63 MLL AF9 63 complement inhibitor eculizumab 63 EoE 63 PARP inhibition 63 Carcinoid tumors 63 Castration Resistant Prostate Cancer 63 invasive carcinomas 63 Metastases 63 Chronic Myeloid Leukemia CML 63 hematologic malignancy 63 hematologic disorders 63 prognostic biomarker 63 Taxol ® 63 Cell Lymphoma 63 alkaline phosphatase ALP 63 grade cervical intraepithelial 63 IDH1 mutation 63 ischemic cardiomyopathy 63 EBRT 63 appendiceal 63 relapsed ovarian cancer 63 patients undergoing CABG 63 Vidaza ® 63 stereotactic radiotherapy 63 intra arterial chemotherapy 63 rectal cancers 63 Group RTOG 63 EndoTAGTM 1 63 idiopathic PAH 63 advanced hepatocellular carcinoma 63 achieved CCyR 63 missense mutations 63 nonsquamous 63 percutaneous cryoablation 63 Metastatic colorectal cancer 63 malignant lesions 63 laryngeal cancer 63 adjuvant therapy 63 metastatic colon cancer 63 stratifying patients 63 kinase inhibition 63 IV melanoma 63 gemcitabine Gemzar ® 63 schwannomas 63 extrapleural pneumonectomy 63 FOLPI 63 CBLC# 63 intracranial hemorrhage ICH 63 pancreatic ductal adenocarcinoma 63 embryonal 63 metastatic disease 63 oral clodronate 63 bile duct cancers 63 pheochromocytomas 63 Squamous cell 63 ERalpha 63 intact parathyroid hormone 63 AA Amyloidosis 63 GnRH agonists 63 cervical lymph node 63 PSMA ADC 63 metastatic renal 63 HbF 63 p# Shc 63 colorectal cancer liver metastases 63 adriamycin 63 Helicobacter pylori infection 63 Critical Limb Ischemia CLI 63 retrospective cohort 63 axillary lymph node dissection 63 colorectal neoplasms 63 Trastuzumab 63 subependymal giant cell 63 GSTT1 63 pancreatic neuroendocrine tumors 63 xenograft 63 Li Fraumeni 63 TTF Therapy 63 FDG PET imaging 63 choriocarcinoma 63 Stage IIIb 63 endometrioid 63 metastatic melanoma 63 pancreatic islet 63 Gliomas 63 PNH patients 63 desmoplastic 63 urothelium 63 AML MDS 63 fibrosarcoma 63 Diabetic nephropathy 63 prognostic indicators 63 TIMP 63 tumor biopsies 63 HER2 amplified 63 Mantle Cell Lymphoma 63 acute myelogenous leukemia AML 63 Fludara ® 63 prognostic marker 63 VATS lobectomy 63 Response Evaluation Criteria 63 lung carcinoma 63 CD# + [001] 63 multimodality therapy 63 antibody mediated 63 BCIRG 63 commercialize deforolimus 63 cytotoxic chemotherapy 63 metastatic cancers 63 ABCB1 63 hypoperfusion 63 hypercoagulable 63 sporadic ALS 63 adenoma 63 PSA nadir 63 chronic myeloid 63 Introgen ADVEXIN 63 proliferative retinopathy 63 FGFR2 63 Velcade bortezomib 63 underwent radical cystectomy 63 recurrent glioma 63 mutational status 63 autologous SCT 63 osteosarcoma Ewing sarcoma 63 prostatic tissue 63 proto oncogene 63 atypical hemolytic uremic syndrome 63 p# biomarkers 63 diffuse gastric 63 GNAQ 63 total thyroidectomy 63 Sudhir Agrawal D.Phil 63 metastatic liver 63 gene polymorphisms 63 EGFR mutation status 63 bendamustine 63 systemic amyloidosis 63 hyperoxaluria 63 T1DM 63 TT genotype 63 peritumoral 63 brain metastases 63 Platinol ® cisplatin 63 unresectable liver cancer 63 BRAF mutations 63 receptor tyrosine kinase inhibitor 63 tumors 63 oesophageal adenocarcinoma 63 cyclin E 63 adjuvant cisplatin 63 lung pancreatic 63 Basal Cell 63 mouse xenograft models 63 ZACTIMA 63 follicular lymphoma 63 autologous hematopoietic stem cell 63 PAOD 63 Sentinel node biopsy 63 EGFRvIII 63 MAGE A3 63 CaP 63 Acute Coronary Syndromes ACS 63 refractory acute myeloid 63 ASCUS 63 Chronic pancreatitis 63 papillomas 63 chemotherapy cisplatin 63 multivariable analysis 63 androgen dependent 63 everolimus eluting stents 63 acute promyelocytic leukemia APL